NCT00160069 is a Phase 2 clinical trial of Sagopilone (BAY86-5302, ZK 219477) in Carcinoma, Non Small Cell Lung, sponsored by Bayer.

Who is sponsoring NCT00160069?

NCT00160069 is sponsored by Bayer.

What drugs are being tested in NCT00160069?

Interventions in NCT00160069: Sagopilone (BAY86-5302, ZK 219477), Sagopilone (BAY86-5302, ZK 219477), Sagopilone (BAY86-5302, ZK 219477).

What condition does NCT00160069 study?

NCT00160069 studies Carcinoma, Non Small Cell Lung.

Is NCT00160069 still recruiting?

NCT00160069 is currently completed. Last updated 2 December 2014.

Last reviewed 2014-12-02 · How we verify

NCT00160069

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC)

Completed Phase 2 Last updated 2 December 2014

What this trial tests

Phase 2 trial testing Sagopilone (BAY86-5302, ZK 219477) in Carcinoma, Non Small Cell Lung in 128 participants. Completed in 1 April 2009.

Timeline

1 August 2005

Primary endpoint
1 April 2008

1 April 2009

Quick facts

Lead sponsor	Bayer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	128
Start date	1 August 2005
Primary completion	1 April 2008
Estimated completion	1 April 2009
Sites	17 locations across Germany

Drugs / interventions tested

Sagopilone (BAY86-5302, ZK 219477) — full drug profile →
Sagopilone (BAY86-5302, ZK 219477) — full drug profile →
Sagopilone (BAY86-5302, ZK 219477) — full drug profile →

Conditions studied

Carcinoma, Non Small Cell Lung — all drugs for Carcinoma, Non Small Cell Lung →

Sponsor

Bayer — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Non Small Cell Lung. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The primary efficacy variable is defined as Proportion of patients with either CR or PR as 'best overall response'. Tumor assessment is performed according to RECIST criteria.
Time frame: Tumor evaluation (MRI or scan) every 2 cycles until disease progression.

Sponsor's own description

Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review.
Chan SHY, Khatib Y, Webley S, Layton D, et al · · 2023 · cited 10× · PMID 37383708 · DOI 10.3389/fphar.2023.1137983

Verify or expand the search:

Other recruiting trials for Carcinoma, Non Small Cell Lung

Currently open trials in the same condition.

NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
NCT06974734 — A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies · Phase 1 · active not recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00160069 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 2 December 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00160069.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing